Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.

scientific article published on 16 July 2013

Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1517/13543784.2013.820275
P8608Fatcat IDrelease_v3ce73ck5fb5tfqihbljzasudi
P698PubMed publication ID23855792

P50authorSerena RuggieriQ56987509
Claudio GasperiniQ57443880
P2093author name stringShalom Haggiag
P2860cites workIgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channelQ24646531
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targetsQ28140238
Ocrelizumab: a step forward in the evolution of B-cell therapyQ28245986
B-cell depletion with rituximab in relapsing-remitting multiple sclerosisQ28268626
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisQ28270998
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disabilityQ28284428
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupQ28293763
Multiple sclerosisQ28299151
IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndromeQ28750403
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelinationQ29614990
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisQ29616119
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectQ33383576
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.Q33565842
High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effectQ33590797
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.Q33899917
Multiple sclerosis: distribution of inflammatory cells in newly forming lesionsQ34089994
Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyQ34096238
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialQ34229618
Risk of natalizumab-associated progressive multifocal leukoencephalopathyQ34275329
Diagnosis and treatment of multiple sclerosisQ34421883
Revised diagnostic criteria for neuromyelitis opticaQ34529345
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignanciesQ34619483
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patientsQ34823634
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammationQ36161486
The immunology of multiple sclerosisQ37078984
The pathological spectrum of CNS inflammatory demyelinating diseasesQ37603085
Predicting responders to therapies for multiple sclerosisQ37606292
CD20 as a target for therapeutic type I and II monoclonal antibodies.Q37720878
EFNS guidelines on diagnosis and management of neuromyelitis opticaQ37763266
Treatment of multiple sclerosis with anti-CD20 antibodiesQ37873643
Variable results after rituximab in neuromyelitis opticaQ37992354
The evidence for a role of B cells in multiple sclerosisQ37993033
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.Q39808939
Interferon beta-1bQ40636802
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialQ44264108
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trialQ45119459
Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.Q47357498
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.Q48200750
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.Q48427388
B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model.Q48437549
CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients.Q48898700
Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.Q50944222
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis.Q51027456
B-cell subsets up-regulate α4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onsetQ51033051
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.Q54195610
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysisQ57753793
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectmultiple sclerosisQ8277
P304page(s)1243-1253
P577publication date2013-07-16
P1433published inExpert Opinion on Investigational DrugsQ5421208
P1476titleDrugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies
P478volume22

Reverse relations

cites work (P2860)
Q36484383Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis
Q57192334Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies
Q35584727The meninges: new therapeutic targets for multiple sclerosis
Q90531435Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies

Search more.